Proactively manage your pharmacy inventory
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Monoquaternary 2,16-bispiperidinylandrostane derivatives|
|Abstract:||Monoquaternary 2,16-bispiperidinylandrostane neuromuscular blocking derivatives having the formula: ##STR1## wherein R.sub.1 is ethyl; R.sub.2 is methyl or allyl; and X.sup.- is a pharmaceutically acceptable anion; or pharmaceutically acceptable salts thereof.|
|Inventor(s):||Sleigh; Thomas (Wishaw, GB6), Carlyle; Ian C. (Hamilton, GB6), Muir; Alan W. (Ravenstruther, GB6)|
|Assignee:||Akzo N.V. (Arnhem, NL)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|92303612||Apr 22, 1992|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||145918||<disabled in preview>|
|Australia||3703093||<disabled in preview>|
|Australia||662277||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.